Role of Oral Lactoferrin in Prevention of Recurnt Bacterial Vaginosis in Pregnancy
Study Details
Study Description
Brief Summary
lactoferrin is believed to modulate immunity and help in prevention of recurrent bacterial vaginosis.In this study, the role of lactoferrin is assessed during third trimester of pregnancy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2/Phase 3 |
Detailed Description
This study will be conducted at Zagazig University Hospitals, Obestetrics and Gynecology department, Zagazig University ,outpatient clinic .Assuming the cure rate was 70.8% vs 33.3% in intervention vs placebo group. At 80% power and 95 % CI, the estimated sample will be 66 cases, 33 cases in each group.
Among enrolled women those who have symptome of bacterial vaginosis will be treated with standard antibiotic therapy (metronidazole 500 mg twice daily for 7 days) and women who have history of recurrent bacterial vaginosis randomly assigned to one of two study arms: study grop receiving lactoferrin (2 capsules/day for 5 days followed by further 10 consecutive days at the dosage of 1 capsule/day) by oral intake.(pravotinR).
And another group not reciving lactoferrin.(control group) During follow-up period, all women ingested 1 capsule of lactoferrin or placebo per day, for 10 consecutive days per month.(study group) .
- All participating women attended 3 visits (from T0 to T2) at the gynaecologic centres at recruitment (T0), swap will be repeated after one month (T1) and two months (T2). In each clinical examination, 2 vaginal swabs (for vaginal culture and Nugent score) will be collected. During the first visit (baseline), patient medical history was recorded, informed consent was signed and women were allocated into the two study arms. - The evaluation of efficacy is based on clinical cure rate of BV symptoms (defined as absence of vaginal discharge or itching), microbiological cure rate (defined as remission and vaginal microbiota improvement by restoration of healthy Nugent score with range 0-3), and overall cure rate (absence of symptoms and Nugent score <7). In addition, recurrence rate was calculated for both groups as percentage of women presenting with symptoms and Nugent score more than 3 during the follow-up period. Safety is assessed by recording all side effects (i.e. adverse events, serious adverse events, and suspected unexpected serious adverse reactions). An adverse event is considered severe if it was fatal, life threatening, required hospitalisation, or led to permanent injury.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: study group study group receiving lactoferrin (2 capsules/day for 5 days followed by further 10 consecutive days at the dosage of 1 capsule/day) by oral intake.(pravotinR). During follow-up period, all women ingested 1 capsule of lactoferrin or placebo per day, for 10 consecutive days per month. |
Drug: lactoferrin
study grop receiving lactoferrin (2 capsules/day for 5 days followed by further 10 consecutive days at the dosage of 1 capsule/day) by oral intake.(pravotin).
And another group not reciving lactoferrin.(control group) During follow-up period, all women ingested 1 capsule of lactoferrin or placebo per day, for 10 consecutive days per month.
Other Names:
|
| Placebo Comparator: control group not recieving lactoferrin |
Drug: lactoferrin
study grop receiving lactoferrin (2 capsules/day for 5 days followed by further 10 consecutive days at the dosage of 1 capsule/day) by oral intake.(pravotin).
And another group not reciving lactoferrin.(control group) During follow-up period, all women ingested 1 capsule of lactoferrin or placebo per day, for 10 consecutive days per month.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- clinical cure rate of bacterial vaginosis symptoms [3 months]
clinical cure rate of bacterial vaginosis symptoms (defined as absence of vaginal discharge or itching)
- microbiological cure rate of bacterial vaginosis [3 months]
defined as remission and vaginal microbiota improvement by restoration of healthy Nugent score with range 0-3), and overall cure rate (absence of symptoms and Nugent score <7)
- recurrence rate of bacterial vaginosis [3 months]
recurrence of bacterial vaginosis symptoms
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Pregnant women of age group 20-37 years.
-
Primigravida.
-
28-40 week gestation.
-
History of receurent bacterial vaginosis .
Exclusion Criteria:
-
Multiple gestations.
-
Multiparity.
-
Medical disorders as:
-
Diabetes mellitus.
-
Chronic hypertension.
-
Endocrinal diseases.
-
Autoimmune diseases.
-
Renal diseases.
-
Blood diseases.
- Allergy to lactoferrin .
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Rania Samy ezzat | Zagazig | Sharqia | Egypt | 00000 |
Sponsors and Collaborators
- Zagazig University
Investigators
- Study Director: Rania Samy Ezzat, MD, Lecturer of obstetrics and Gynecology, Faculty of Medicine, Zagazig University
- Study Chair: Amal Mohamed Alanwar, MD, Professor of obstetrics and Gynecology, Faculty of Medicine, Zagazig University
- Study Director: Safaa Abdelsalam Ibrahim, MD, Professor of obstetrics and Gynecology, Faculty of Medicine, Zagazig University
- Study Director: Marian Asaad Gerges, MD, Assistant Professor of Microbiology and Immunology Faculty of Medicine Zagazig University
- Principal Investigator: Khoulh Al Mahdi Anbeeh Al Barhami, MBBCH, Master's degree candidate
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ZU-IRB #9639/5-7-2022